神经纤维状结可以预测患有动脉狭窄症的患者的痴呆症
Summan Zahra1, Kaneez Zahra Rubab Khakwani1, Daniela Acosta1
1Department of Surgery; University of Arizona College of Medicine, Tucson, Arizona, USA.
Journal of vascular surgery
|February 26, 2025
概括
额外带动脉样硬化病 (ECAD) 与痴呆风险有关. 单独的神经纤维状结 (NFT) 在ECAD患者中显示出痴呆症的高预测价值,这表明未来的血液测试可以识别有风险的个体.
科学领域:
- 神经学 神经学
- 心血管科学 心血管科学
- 老年学是一门学科.
背景情况:
- 额外带动脉样硬化病 (ECAD) 越来越多地被认为是痴呆的危险因素.
- 目前ECAD的临床管理缺乏认知结果评估或痴呆风险分层.
- 识别患有痴呆症高风险的ECAD个体对于主动干预至关重要.
研究的目的:
- 调查与ECAD患者痴呆相关的临床和组织病理因素.
- 在ECAD队列中确定痴呆风险的可靠预测指标.
- 在ECAD中探索用于痴呆症预测的各种生物标志物的诊断准确性.
主要方法:
- 进行了一项前性临床病理学研究 (亚利桑那州衰老和神经退行性疾病研究).
- 111名ECAD患者被评估是否患有痴呆症 (阿尔茨海默病和/或血管痴呆症).
- 后勤回归和精确回忆曲线分析了风险因素,包括年龄,性别,心血管因素,APOE4状态和痴呆症生物标志物,如神经纤维状结 (NFT) 和粉样斑.
主要成果:
- 患有痴呆症的个人表现出较高的中风,APOE4基因型,NFT和粉样斑块的患病率.
- 单独的神经纤维状结 (NFT) 显示出对痴呆的高正预测值 (96.9%).
- 综合风险因素模型显示,在预测痴呆症方面,相对于单独的NFT,其改善程度很小.
结论:
- 神经纤维状结 (NFTs) 成为ECAD患者痴呆风险最强的预测因素.
- 这些发现表明,NFT量化,可能通过未来的基于血液的测试,可以识别患有痴呆症风险较高的ECAD患者.
- 这项研究突出了ECAD管理中改善痴呆风险分层的潜力.
相关概念视频
01:30Dementia
88
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
88
01:37Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
01:26Alzheimer's Disease: Overview
422
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
422
01:22Alzheimer's Disease: Treatment
147
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
147
03:03Amyloid Fibrils
9.2K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.2K